Analyst Reco. Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Delayed Nasdaq Other stock markets 03:50:10 2024-05-28 pm EDT			5-day change	1st Jan Change
38.2 ^USD	+25.62%		+27.30%	+20.52%

12:30pm	Arcturus Therapeutics Holdings Inc. Announces Positive Development for Cystic Fibrosis Program	CI
May. 22	Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	Mar. 21	MT
Canaccord Genuity Adjusts Arcturus Therapeutics Holdings' PT to $87 From $81, Maintains Buy Rating	Mar. 11	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $58 From $45, Maintains Overweight Rating	Mar. 08	MT
Citigroup Raises Price Target on Arcturus Therapeutics to $48 From $40, Maintains Buy Rating	Feb. 08	MT
Canaccord Genuity Initiates Arcturus Therapeutics With Buy Rating, $81 Price Target	Dec. 13	MT
William Blair Initiates Arcturus Therapeutics Holdings at Outperform Rating	23-07-24	MT
HC Wainwright Upgrades Arcturus Therapeutics Holdings to Buy From Neutral, Price Target at $51	23-05-11	MT
Goldman Sachs Adjusts Price Target on Arcturus Therapeutics Holdings to $14 From $8, Maintains Sell Rating	22-11-10	MT
Baird Downgrades Arcturus Therapeutics Holdings to Underperform From Neutral, Price Target is $18	22-11-10	MT
Barclays Upgrades Arcturus Therapeutics Holdings to Equalweight From Underweight, Adjusts Price Target to $25 From $16	22-11-02	MT
Arcturus Therapeutics Shares Rise 31% After Vaccine Collaboration	22-11-02	DJ
Cantor Fitzgerald Raises Price Target on Arcturus Therapeutics Holdings to $44 From $39, Keeps Overweight Rating	22-11-02	MT
US Futures Nudge Higher Ahead of Federal Reserve Board Meeting; Fourth Straight Rate Hike Expected	22-11-02	MT
Wells Fargo Adjusts Price Target on Arcturus Therapeutics Holdings to $98 From $105, Reiterates Overweight Rating	22-08-10	MT
Barclays Trims Price Target on Arcturus Therapeutics Holdings to $16 From $17, Reiterates Underweight Rating	22-08-10	MT
Raymond James Downgrades Arcturus Therapeutics Holdings to Underperform From Market Perform	22-08-10	MT
Cantor Fitzgerald Assumes Arcturus Therapeutics Holdings at Overweight, Sets $39 Price Target	22-07-19	MT
Goldman Sachs Adjusts Arcturus Therapeutics Holdings' Price Target to $8 from $14, Keeps Sell Rating	22-05-24	MT
Baird Upgrades Arcturus Therapeutics Holdings to Neutral From Underperform, Cuts Price Target to $18 From $21	22-05-11	MT
Barclays Adjusts Arcturus Therapeutics Holdings' Price Target to $17 from $21, Keeps Underweight Rating	22-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Analyst Reco.

Filters